Musumeci R, De Palo G, Conti U, Kenda R, Mangioni C, Belloni C, Marzi M, Bandieramonte G
Cancer. 1980 Oct 15;46(8):1887-92. doi: 10.1002/1097-0142(19801015)46:8<1887::aid-cncr2820460831>3.0.co;2-1.
The results of foot lymphography in 295 patients with endometrial carcinoma observed from 1968 to 1978 at two institutions are reported. One hundred and eighty-two were new cases, 61 were recurrences, and 52 were patients who underwent restaging diagnostic procedures without clinical evidence of disease. The incidence of lymphatic spread was correlated with the clinical stage, the pathologic stage, and the extent of recurrent disease. In fact, in the 182 new cases, at clinical stage, the pathologic stage, lymphography was positive in 8.9% of patients at Stage I, 28.6% at Stage II, 57.1% at Stage III, and 66.6% at Stage IV disease; at pathological stage, lymphography was positive in 8% of patients at Stage I, 14.8% at Stage II, 39.3% at Stage II, and 53.3% at Stage IV disease. There was lymph node involvement in 47.5% of the 61 pretreated patients. Finally, in 52 pretreated patients with no evidence of disease, the incidence of lymph node involvement was 7.7%. In new cases, metastases were found only in the pelvic nodes in 56.2% of the patients and only in the para-aortic nodes in 9.5%; in 34.3%, both chains were simultaneously involved. The five-year survival rate for patients at Stage I, II, and III disease with positive lymphography was 35% as compared with 73% for negative cases. In patients at Stage I and II, the difference of survival was equal to 24%. The reliability of the results is confirmed by the concordance with the data of the literature on histologic involvement, by the first radiologic-pathologic comparison, and by the clinical course of the positive cases. Lymphography is of unquestionable value for an appropriate staging and for a correct plan of treatment.
报告了1968年至1978年在两家机构对295例子宫内膜癌患者进行足部淋巴造影的结果。其中182例为新病例,61例为复发病例,52例为接受再分期诊断程序但无疾病临床证据的患者。淋巴转移发生率与临床分期、病理分期及复发疾病范围相关。事实上,在182例新病例中,临床分期方面,I期患者淋巴造影阳性率为8.9%,II期为28.6%,III期为57.1%,IV期为66.6%;病理分期方面,I期患者淋巴造影阳性率为8%,II期为14.8%,III期为39.3%,IV期为53.3%。61例接受过治疗的患者中有47.5%发生淋巴结受累。最后,52例无疾病证据的接受过治疗的患者中,淋巴结受累发生率为7.7%。在新病例中,56.2%的患者转移仅发生在盆腔淋巴结,9.5%仅发生在腹主动脉旁淋巴结;34.3%的患者两条淋巴链同时受累。淋巴造影阳性的I、II、III期患者五年生存率为35%,而阴性病例为73%。在I期和II期患者中,生存率差异为24%。与组织学受累的文献数据的一致性、首次放射学与病理学比较以及阳性病例的临床病程均证实了结果的可靠性。淋巴造影对于恰当的分期和正确的治疗方案具有毋庸置疑的价值。